MedPath
HSA Approval

VISIPAQUE INJECTION 270 mgI/ml

SIN08882P

VISIPAQUE INJECTION 270 mgI/ml

VISIPAQUE INJECTION 270 mgI/ml

August 28, 1996

GE HEALTHCARE PTE. LTD.

GE HEALTHCARE PTE. LTD.

Regulatory Information

GE HEALTHCARE PTE. LTD.

GE HEALTHCARE PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

INJECTION

**Posology and method of administration** The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually approximately the same iodine concentration and volume is used as with other iodinated X-ray contrast media in current use, but adequate diagnostic information has also been obtained in some studies with iodixanol injection with somewhat lower iodine concentration. Adequate hydration should be assured before and after administration as for other contrast media. The product is for intravenous, intra-arterial and intrathecal use. The following dosages may serve as a guide. The doses given for intra-arterial use are for single injections that may be repeated. ![Visipaque Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/34fe065fcd4d2753ef972ecbe12122c0.png) **Elderly: As for other adults**

INTRAVENOUS, INTRA-ARTERIAL, INTRATHECAL

Medical Information

**Indications** X-ray contrast medium for cardioangiography, cerebral angiography (conventional), peripheral arteriography (conventional), abdominal angiography (i.a. DSA), urography, venography, CT- enhancement. Lumbar, thoracic and cervical myelography.

**Contraindications** Hypersensitivity to the active substance or to any of the excipients. Manifest thyrotoxicosis.

V08AB09

iodixanol

Manufacturer Information

GE HEALTHCARE PTE. LTD.

GE HEALTHCARE IRELAND LIMITED (by Parametric Release)

GE HEALTHCARE AS (by Parametric Release)

GE HEALTHCARE (SHANGHAI) CO., LTD

Active Ingredients

IODIXANOL

550 mg/ml

Iodixanol

Documents

Package Inserts

Visipaque Injection PI.pdf

Approved: November 19, 2020

Download
© Copyright 2025. All Rights Reserved by MedPath